Cancer Journal

Overview

publication venue for

• Patient-derived xenografts for individualized care in advanced sarcoma. 2014
• 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. 1999
• Familial neuroblastoma. Case reports, literature review, and etiologic considerations. 1986
• Splenic rupture in patients with hematologic malignancies. 1981
• Surgical repair of esophagobronchial fistula following successful treatment of Hodgkin's disease. 1979
• Immunoblastic lymphadenopathy and adenocarcinoma of the pancreas: a case report. 1978
• Hodgkin's disease and granulomatous angiitis of the central nervous system. 1976
• Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. 2024
• Breastfeeding experiences among young breast cancer survivors: A survey study. 2024
• Role of primary care in opioid prescribing for older head and neck cancer survivors. 2024
• Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening. 2024
• Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality. 2024
• Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial. 2024
• Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative. 2024
• SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer. 2024
• Prognosis and risk of suicide after cancer diagnosis. 2023
• Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. 2023
• Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. 2023
• Pathogenic germline variants in patients with endometrial cancer of diverse ancestry. 2023
• Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors. 2023
• Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model..  130. 2023
• Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. 2023
• Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors..  129. 2023
• Mammography screening beliefs and barriers through the lens of Black women during the COVID-19 pandemic..  129. 2023
• Determinants of overall survival in patients with metastatic uveal melanoma..  129. 2023
• Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis..  129. 2023
• Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial..  129. 2023
• Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study. 2023
• The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study. 2023
• What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing. 2022
• Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants..  128. 2022
• Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma..  128. 2022
• Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States..  128. 2022
• Association between immigrant status and advanced cancer patients' location and quality of death. 2022
• Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors. 2022
• "Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. 2022
• Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. 2021
• Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers..  128. 2021
• Have urinary function outcomes after radical prostatectomy improved over the past decade? 2021
• Trajectories of fear of cancer recurrence in young breast cancer survivors. 2021
• Identifying and describing cancer survivors: Implications for cancer survivorship research and clinical care..  128. 2021
• Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. 2021
• Economic distress, financial toxicity, and medical cost-coping in young adult cancer survivors during the COVID-19 pandemic: Findings from an online sample..  127. 2021
• Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes..  127. 2021
• Treatment patterns and survival in patients with early-onset pancreatic cancer..  127. 2021
• Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVID-19 pandemic among low-income women in New York City..  127. 2021
• Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors..  127. 2021
• Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)..  127. 2021
• Geospatial access predicts cancer stage at presentation and outcomes for patients with breast cancer in southwest Nigeria: A population-based study..  127. 2021
• Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)..  127. 2021
• Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation..  127. 2021
• Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies..  127. 2021
• Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy..  127. 2020
• Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers..  127. 2020
• Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer..  127. 2020
• Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial..  126. 2020
• Clinical implications of drug-induced liver injury in early-phase oncology clinical trials..  126. 2020
• A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma..  126. 2020
• Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes..  126. 2020
• Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver..  126. 2020
• The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer..  126. 2020
• Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma..  126. 2020
• Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer..  126. 2020
• Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men..  126. 2020
• 11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood..  126. 2020
• Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial..  126. 2020
• Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance..  126. 2020
• Differences in ambulatory care fragmentation between cancer survivors and noncancer controls..  126. 2020
• Distant metastasis of salivary gland cancer: Incidence, management, and outcomes..  126. 2020
• Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies..  126. 2020
• Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings..  126. 2020
• Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study..  126. 2020
• Physician and facility drivers of spending variation in locoregional prostate cancer..  126. 2020
• Genomic and clinical characterization of stromal infiltration markers in prostate cancer..  126. 2020
• The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study..  126. 2020
• Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma..  126. 2019
• Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway..  126. 2019
• Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer..  126. 2019
• Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis..  126. 2019
• "My doctor says the cancer is worse, but I believe in miracles"-When religious belief in miracles diminishes the impact of news of cancer progression on change in prognostic understanding..  126. 2019
• Barriers and facilitators of risk-based health care for adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  126. 2019
• Is screening for psychosocial risk factors associated with mental health care in older adults with cancer undergoing surgery?.  126. 2019
• Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer..  126. 2019
• Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network..  126. 2019
• Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin..  125. 2019
• Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers..  125. 2019
• Obesity and breast cancer screening: Cross-sectional survey results from the behavioral risk factor surveillance system..  125. 2019
• Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma..  125. 2019
• Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer..  125. 2019
• Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)..  125. 2019
• Association between advanced cancer patient-caregiver agreement regarding prognosis and hospice enrollment..  125. 2019
• Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer..  125. 2019
• Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  125. 2019
• A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas..  125. 2019
• Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms..  125. 2019
• Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer..  125. 2019
• A scale to assess religious beliefs in end-of-life medical care..  125. 2019
• A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study..  125. 2019
• The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study..  125. 2019
• A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma..  125. 2019
• Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes..  125. 2019
• Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?.  125. 2019
• Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes..  125. 2018
• Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy..  125. 2018
• Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study..  125. 2018
• Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations..  125. 2018
• Estimating child mortality associated with maternal mortality from breast and cervical cancer..  125. 2018
• Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial..  124. 2018
• Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer..  124. 2018
• Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer..  124. 2018
• Symptom and function profiles of men with localized prostate cancer..  124. 2018
• A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer..  124. 2018
• Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure..  124. 2018
• Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial..  124. 2018
• Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life..  124. 2018
• Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA..  124. 2018
• Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer..  124. 2018
• Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  124. 2018
• Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma..  124. 2018
• Bone biopsy protocol for advanced prostate cancer in the era of precision medicine..  124. 2017
• Travel distance and stereotactic body radiotherapy for localized prostate cancer..  124. 2017
• Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia..  124. 2017
• Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness..  123. 2017
• Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases..  124. 2017
• Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis..  124. 2017
• Comparison of recommendations for screening mammography using CISNET models..  123. 2017
• A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma..  123. 2017
• Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum..  123. 2017
• Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer..  123. 2017
• Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer..  123. 2017
• Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation..  123. 2017
• Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics..  123. 2017
• The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis..  123. 2017
• Androgen receptor-positive, triple-negative breast cancer..  123. 2017
• Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation..  123. 2017
• A comprehensive comparative analysis of treatment modalities for sinonasal malignancies..  123. 2017
• Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma..  123. 2017
• Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?.  123. 2017
• Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study..  123. 2017
• Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel..  123. 2017
• Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma..  123. 2017
• Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract..  123. 2017
• Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation..  123. 2017
• Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes..  123. 2017
• A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence..  123. 2017
• Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer..  123. 2016
• The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era..  123. 2016
• A prospective cohort study of patients with peripheral T-cell lymphoma in the United States..  123. 2016
• Clinical and genetic determinants of ovarian metastases from colorectal cancer..  123. 2016
• An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi..  123. 2016
• Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases..  123. 2016
• Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)..  123. 2016
• A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck..  122. 2016
• Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial..  123. 2016
• A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)..  122. 2016
• Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods..  123. 2016
• Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies..  122. 2016
• The efficacy of anti-PD-1 agents in acral and mucosal melanoma..  122. 2016
• Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy..  122. 2016
• Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up..  123. 2016
• Patient function, long-term survival, and use of surgery in patients with kidney cancer..  122. 2016
• Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study..  122. 2016
• White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue..  122. 2016
• Genomic characterization of response to chemoradiation in urothelial bladder cancer..  122. 2016
• Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis..  122. 2016
• Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)..  122. 2016
• National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?.  122. 2016
• Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy..  122. 2016
• Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision..  122. 2016
• Patient experience and quality of urologic cancer surgery in US hospitals..  122. 2016
• Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer..  122. 2016
• Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care..  122. 2016
• Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation..  122. 2016
• Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme..  122. 2016
• Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)..  122. 2016
• Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma..  122. 2016
• Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information..  122. 2016
• Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research..  122. 2016
• Impact of end-of-life discussions on the reduction of Latino/non-Latino disparities in do-not-resuscitate order completion..  122. 2016
• Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base..  122. 2016
• Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program..  122. 2016
• Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status..  122. 2016
• Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma..  122. 2016
• Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study..  122. 2016
• Impact of vision loss among survivors of childhood central nervous system astroglial tumors..  122. 2016
• Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies..  122. 2016
• Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium..  122. 2015
• Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone..  122. 2015
• The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents..  122. 2015
• Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies..  122. 2015
• Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma..  122. 2015
• Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer..  122. 2015
• Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients..  122. 2015
• The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base..  122. 2015
• Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma..  122. 2015
• Identification of germline genetic mutations in patients with pancreatic cancer..  121. 2015
• Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening..  121. 2015
• Extent of resection and overall survival for patients with atypical and malignant meningioma..  121. 2015
• Population-based assessment of determining predictors for quality of prostate cancer surveillance..  121. 2015
• Cost-effectiveness analysis of papillary thyroid cancer surveillance..  121. 2015
• Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT..  121. 2015
• Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications..  121. 2015
• Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib..  121. 2015
• Disparities in survival by insurance status in patients with Hodgkin lymphoma..  121. 2015
• The lasting impact of the therapeutic alliance: Patient-oncologist alliance as a predictor of caregiver bereavement adjustment..  121. 2015
• Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey..  121. 2015
• Male-female patient differences in the association between end-of-life discussions and receipt of intensive care near death..  121. 2015
• The effect of oncologists' exercise recommendations on the level of exercise and quality of life in survivors of breast and colorectal cancer: A randomized controlled trial..  121. 2015
• Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas..  121. 2015
• Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy..  121. 2015
• Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis..  121. 2015
• Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates..  121. 2015
• Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma..  121. 2014
• The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study..  121. 2014
• Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma..  121. 2014
• RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer..  121. 2014
• Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium..  121. 2014
• A mixed-methods examination of communication between oncologists and primary care providers among primary care physicians in underserved communities..  121. 2014
• Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium..  121. 2014
• Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group..  121. 2014
• Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes..  120. 2014
• Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma..  121. 2014
• KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases..  120. 2014
• Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients..  121. 2014
• End-of-life treatment preferences: a key to reducing ethnic/racial disparities in advance care planning?.  120. 2014
• US lung cancer trends by histologic type..  120. 2014
• Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database..  120. 2014
• Suicidal ideation in prostate cancer survivors: understanding the role of physical and psychological health outcomes..  120. 2014
• Patient-oncologist alliance as protection against suicidal ideation in young adults with advanced cancer..  120. 2014
• Treatment-related amenorrhea and sexual functioning in young breast cancer survivors..  120. 2014
• Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study..  120. 2014
• Daughters and Mothers Against Breast Cancer (DAMES): main outcomes of a randomized controlled trial of weight loss in overweight mothers with breast cancer and their overweight daughters..  120. 2014
• Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy..  120. 2014
• A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study..  120. 2014
• Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy..  120. 2014
• Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project..  120. 2014
• BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer..  120. 2014
• Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network..  120. 2014
• Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era..  120. 2014
• The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: evidence to support a revision of the American Joint Committee on Cancer staging system..  120. 2014
• Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program..  120. 2014
• Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma..  120. 2014
• Causes of death in long-term survivors of head and neck cancer..  120. 2014
• Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period..  120. 2014
• A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib..  120. 2014
• Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue..  120. 2014
• Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710..  120. 2014
• Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty..  120. 2013
• Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms..  120. 2013
• An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer..  120. 2013
• ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer..  120. 2013
• Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective..  120. 2013
• The end-of-life experience: modifiable predictors of caregivers' bereavement adjustment..  120. 2013
• Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma..  120. 2013
• Reducing time-to-treatment in underserved Latinas with breast cancer: the Six Cities Study..  120. 2013
• Breast cancer presentation and diagnostic delays in young women..  120. 2013
• Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma..  120. 2013
• Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group..  120. 2013
• Suicide ideation and associated mortality in adult survivors of childhood cancer..  120. 2013
• TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial..  119. 2013
• Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study..  119. 2013
• Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study..  119. 2013
• Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials..  119. 2013
• Changes in the availability of screening mammography, 2000-2010..  119. 2013
• A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701..  119. 2013
• Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project..  119. 2013
• Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience..  119. 2013
• The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)..  119. 2013
• Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer..  119. 2013
• The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome..  119. 2013
• Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma..  119. 2013
• Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody..  119. 2013
• Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer..  119. 2013
• Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older..  119. 2013
• Expression of androgen receptor and its phosphorylated forms in breast cancer progression..  119. 2013
• Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study..  119. 2013
• Health care-associated infections after major cancer surgery: temporal trends, patterns of care, and effect on mortality..  119. 2013
• External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma..  119. 2013
• RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics..  119. 2013
• Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer..  119. 2013
• A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer..  119. 2013
• Association between exercise and primary incidence of prostate cancer: does race matter?.  119. 2013
• Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)..  119. 2013
• A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas..  119. 2013
• Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients..  119. 2012
• Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up..  119. 2012
• Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial..  119. 2012
• Navigating Latinas with breast screen abnormalities to diagnosis: the Six Cities Study..  119. 2012
• Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program..  119. 2012
• Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program..  119. 2012
• Long-term regional control and survival in patients with "low-risk," early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness..  119. 2012
• Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer..  119. 2012
• ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma..  119. 2012
• Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision..  119. 2012
• Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer..  119. 2012
• Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma..  119. 2012
• Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial..  119. 2012
• Elderly patients with colon cancer have unique tumor characteristics and poor survival..  119. 2012
• BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer..  119. 2012
• Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women..  119. 2012
• Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer..  118. 2012
• Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion..  119. 2012
• Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008..  119. 2012
• Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas..  119. 2012
• Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences..  118. 2012
• Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial..  119. 2012
• Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy..  118. 2012
• A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer..  118. 2012
• Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics..  118. 2012
• Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma..  118. 2012
• Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas..  118. 2012
• Fractures among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..  118. 2012
• Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial..  118. 2012
• Measuring psychosocial distress and parenting concerns among adults with cancer: the Parenting Concerns Questionnaire..  118. 2012
• Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer..  118. 2012
• Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older..  118. 2012
• Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis..  118. 2012
• A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors..  118. 2012
• Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors..  118. 2012
• A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer..  118. 2012
• Costs and trends in pancreatic cancer treatment..  118. 2012
• Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy..  118. 2012
• Leapfrog volume thresholds and perioperative complications after radical prostatectomy..  118. 2012
• Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors..  118. 2012
• Use of complementary medications among older adults with cancer..  118. 2012
• Disparities in access to care at high-volume institutions for uro-oncologic procedures..  118. 2012
• Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study..  118. 2012
• Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group..  118. 2012
• Single versus multiple primary melanomas: old questions and new answers..  118. 2012
• Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782..  118. 2011
• Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma..  118. 2011
• Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma..  118. 2011
• Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008..  118. 2011
• Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer..  118. 2011
• Durable remission with salvage second autotransplants in patients with multiple myeloma..  118. 2011
• Young women with family history of breast cancer and their risk factors for benign breast disease..  118. 2011
• Androgen deprivation and thromboembolic events in men with prostate cancer..  118. 2011
• Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study..  118. 2011
• Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas..  118. 2011
• Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis..  118. 2011
• Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma..  118. 2011
• Patient satisfaction and health-related quality of life after autologous tissue breast reconstruction: a prospective analysis of early postoperative outcomes..  118. 2011
• 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response..  118. 2011
• Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment..  118. 2011
• A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer..  118. 2011
• Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database..  118. 2011
• Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer..  118. 2011
• Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer..  118. 2011
• The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy..  118. 2011
• Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study..  118. 2011
• Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation..  118. 2011
• Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States..  118. 2011
• Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma..  118. 2011
• A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid..  118. 2011
• Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer..  118. 2011
• Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection..  118. 2011
• Morbidity and mortality of radical prostatectomy differs by insurance status..  118. 2011
• Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study..  118. 2011
• Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis..  118. 2011
• Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States..  118. 2011
• Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design..  118. 2011
• Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809..  117. 2011
• A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma..  118. 2011
• Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision..  118. 2011
• Early stage squamous cell cancer of the oral tongue--clinicopathologic features affecting outcome..  118. 2011
• The enigma of myxofibrosarcoma of the extremity..  118. 2011
• Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)..  118. 2011
• Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome..  117. 2011
• Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer..  117. 2011
• Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer..  117. 2011
• Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer..  118. 2011
• Research challenges in adolescent and young adult cancer survivor research..  117. 2011
• The cancer is over, now what?: Understanding risk, changing outcomes..  117. 2011
• A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends..  117. 2011
• Support of cancer patients' spiritual needs and associations with medical care costs at the end of life..  117. 2011
• Patients rate physician communication about lung cancer..  117. 2011
• Reirradiation for recurrent medulloblastoma..  117. 2011
• Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy..  117. 2011
• Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival..  117. 2011
• Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy..  117. 2011
• Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy..  117. 2011
• Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer..  117. 2011
• Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis..  117. 2011
• Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies..  117. 2011
• Utilization and expense of adjuvant cancer therapies following radical prostatectomy..  117. 2011
• Conditional survival predictions after surgery for patients with penile carcinoma..  117. 2011
• Prospective study of growth and development in older girls and risk of benign breast disease in young women..  117. 2011
• Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity..  117. 2011
• Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis..  117. 2011
• Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations..  117. 2011
• Studying cancer in minorities: a look at the numbers..  117. 2011
• Clinical outcomes for patients with soft tissue sarcoma of the hand..  117. 2011
• Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study..  117. 2010
• Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy..  117. 2010
• Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer..  116. 2010
• Evaluation of lymph node counts in primary retroperitoneal lymph node dissection..  116. 2010
• A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus..  117. 2010
• Addition of pamidronate to chemotherapy for the treatment of osteosarcoma..  117. 2010
• Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival..  117. 2010
• Patient satisfaction with postmastectomy breast reconstruction: a comparison of saline and silicone implants..  116. 2010
• Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression..  117. 2010
• Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement..  117. 2010
• African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study..  116. 2010
• Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion..  116. 2010
• Methylphenidate for fatigue in ambulatory men with prostate cancer..  116. 2010
• Expanding colorectal cancer screening among minority women..  117. 2010
• Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50..  117. 2010
• Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas..  116. 2010
• Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer..  116. 2010
• A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer..  117. 2010
• Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study..  117. 2010
• Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience..  116. 2010
• Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography..  116. 2010
• Influence of patients' preferences and treatment site on cancer patients' end-of-life care..  116. 2010
• Craniofacial resection for malignant tumors involving the skull base in the elderly: an international collaborative study..  117. 2010
• Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma..  117. 2010
• A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography..  116. 2010
• Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database..  116. 2010
• Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma..  117. 2010
• Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors..  116. 2010
• Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma..  116. 2010
• A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer..  117. 2010
• Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals..  116. 2010
• Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life..  116. 2010
• Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram..  116. 2010
• Highly predictive survival nomogram after upper urinary tract urothelial carcinoma..  116. 2010
• Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I..  116. 2010
• The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials..  116. 2010
• Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study..  116. 2010
• Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma..  116. 2010
• A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score..  116. 2010
• A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer..  116. 2010
• Detection of minimal residual disease in blood and bone marrow in early stage breast cancer..  116. 2010
• Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study..  116. 2010
• Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma..  116. 2010
• Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study..  116. 2010
• Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma..  116. 2010
• Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden..  116. 2010
• Trends in renal tumor surgery delivery within the United States..  116. 2010
• Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)..  116. 2010
• Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?.  116. 2010
• Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker..  116. 2010
• Anxiety disorders in advanced cancer patients: correlates and predictors of end-of-life outcomes..  116. 2010
• Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas..  116. 2010
• Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma..  116. 2010
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival..  116. 2010
• Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy..  116. 2010
• Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099..  116. 2010
• Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?.  116. 2010
• A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer..  116. 2010
• Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803..  116. 2010
• Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer..  116. 2010
• Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma..  116. 2010
• Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study..  116. 2010
• Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign..  116. 2010
• Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation..  116. 2010
• Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study..  116. 2010
• Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma..  117. 2009
• Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study..  115. 2009
• Lymph node density is a significant predictor of outcome in patients with oral cancer..  115. 2009
• Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective..  115. 2009
• Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach..  115. 2009
• Ethnic disparity in mortality after diagnosis of colorectal cancer among inner city minority New Yorkers..  115. 2009
• Identification of borderline thyroid tumors by gene expression array analysis..  115. 2009
• Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium..  115. 2009
• Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group..  115. 2009
• Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma..  115. 2009
• Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma..  115. 2009
• A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years..  115. 2009
• Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population..  117. 2009
• Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials..  115. 2009
• Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study..  115. 2009
• Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer..  115. 2009
• Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial..  115. 2009
• Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations..  117. 2009
• Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale..  115. 2009
• Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver..  115. 2009
• EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer..  115. 2009
• Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma..  115. 2009
• Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study..  115. 2009
• Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland..  115. 2009
• Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia..  115. 2009
• Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies..  115. 2009
• Radical versus partial nephrectomy: effect on overall and noncancer mortality..  115. 2009
• Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000..  115. 2009
• Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy..  115. 2009
• Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration..  115. 2009
• Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process..  115. 2009
• Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541..  115. 2009
• Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer..  115. 2009
• Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy..  115. 2009
• EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer..  117. 2009
• Reflex UroVysion testing in suspicious urine cytology cases..  117. 2009
• A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma..  115. 2009
• Hypofractionated stereotactic radiotherapy for the treatment of brain metastases..  115. 2009
• Comparison of models to predict clinical failure after radical prostatectomy..  115. 2009
• Mental health, treatment preferences, advance care planning, location, and quality of death in advanced cancer patients with dependent children..  115. 2009
• Survival of distinct Asian groups among colorectal cancer cases in California..  115. 2009
• Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh..  115. 2009
• Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors..  115. 2009
• Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study..  114. 2008
• Changes in the presentation of nodular and superficial spreading melanomas over 35 years..  113. 2008
• Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy..  113. 2008
• Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study..  113. 2008
• A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location..  113. 2008
• Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma..  113. 2008
• A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience..  113. 2008
• Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia..  113. 2008
• Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?.  113. 2008
• Merkel cell carcinoma: histologic features and prognosis..  113. 2008
• Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma..  113. 2008
• Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation..  113. 2008
• Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma..  113. 2008
• Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer..  113. 2008
• Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel..  113. 2008
• Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme..  113. 2008
• Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy..  113. 2008
• Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004..  113. 2008
• Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers..  113. 2008
• High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma..  113. 2008
• Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms..  113. 2008
• Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma..  113. 2008
• Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation..  113. 2008
• Survival rates after resection for localized kidney cancer: 1989 to 2004..  113. 2008
• Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria..  114. 2008
• Cervical cancer in patients infected with the human immunodeficiency virus..  112. 2008
• Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy..  112. 2008
• Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer..  112. 2008
• Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy..  112. 2008
• Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up..  112. 2008
• Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer..  112. 2008
• Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with terminal illness..  112. 2008
• Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy..  112. 2008
• Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients..  112. 2008
• Prognostic significance of HER-2 status in women with inflammatory breast cancer..  112. 2008
• Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study..  112. 2008
• Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens..  114. 2008
• Correlates of patient satisfaction and provider trust after breast-conserving surgery..  112. 2008
• Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy..  112. 2008
• Proxy perspectives regarding end-of-life care for persons with cancer..  112. 2008
• Changing indications for surgery in patients with stage IV breast cancer: a current perspective..  112. 2008
• Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation..  112. 2008
• Symptom burden after autologous stem cell transplantation for multiple myeloma..  112. 2008
• Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?.  112. 2008
• Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas..  112. 2008
• Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium..  112. 2008
• Cytologic findings after fertility-sparing radical trachelectomy..  114. 2008
• The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor..  112. 2008
• Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)..  112. 2008
• Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy..  112. 2008
• Bcl-6 predicts improved prognosis in primary central nervous system lymphoma..  112. 2008
• Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent..  112. 2008
• Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial..  110. 2007
• Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma..  110. 2007
• Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis..  110. 2007
• Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung..  110. 2007
• Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging..  110. 2007
• Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration..  110. 2007
• Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease..  110. 2007
• Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study..  110. 2007
• Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation..  110. 2007
• Patterns of treatment in older adults with primary central nervous system lymphoma..  110. 2007
• Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study..  110. 2007
• Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma..  110. 2007
• Liquid-based Papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: study of 272 cases classified by the 2001 Bethesda system..  111. 2007
• Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer..  110. 2007
• Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions..  110. 2007
• Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer..  110. 2007
• Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity..  110. 2007
• Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?.  110. 2007
• Hepatic metastasectomy in children..  109. 2007
• Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction..  109. 2007
• Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma..  109. 2007
• Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis..  109. 2007
• Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943..  109. 2007
• Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells..  109. 2007
• Management of primary liver sarcomas..  109. 2007
• Survivin expression is associated with bladder cancer presence, stage, progression, and mortality..  109. 2007
• Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome..  109. 2007
• Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy..  109. 2007
• Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors..  109. 2007
• Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function..  109. 2007
• EphA2 overexpression is associated with angiogenesis in ovarian cancer..  109. 2007
• Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases..  109. 2007
• A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma..  107. 2006
• Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer..  107. 2006
• FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease..  107. 2006
• Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression..  107. 2006
• Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?.  107. 2006
• Grading follicular lymphomas in fine-needle aspiration biopsies: the role of ThinPrep slides and flow cytometry..  108. 2006
• New York City's immigrant minorities. Reducing cancer health disparities..  107. 2006
• Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma..  107. 2006
• Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?.  107. 2006
• Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival..  107. 2006
• Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis..  107. 2006
• Treatment of metastatic sarcoma to the liver with bland embolization..  107. 2006
• Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity..  107. 2006
• The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study..  107. 2006
• A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach..  107. 2006
• A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer..  107. 2006
• Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients..  108. 2006
• Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder..  107. 2006
• A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015..  107. 2006
• Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma..  107. 2006
• The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor..  107. 2006
• Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue..  106. 2006
• Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients..  106. 2006
• Selecting patients for breast-conserving therapy: the importance of lobular histology..  106. 2006
• Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy..  106. 2006
• Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma..  106. 2006
• Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ..  106. 2006
• Patterns of exercise across the cancer trajectory in brain tumor patients..  106. 2006
• Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa..  106. 2006
• Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer..  106. 2006
• Outcome of patients with fibrolamellar hepatocellular carcinoma..  106. 2006
• Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients..  106. 2006
• Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma..  106. 2006
• Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy..  106. 2006
• Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes..  106. 2006
• Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma..  106. 2006
• Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma..  106. 2006
• Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma..  106. 2006
• Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival..  106. 2006
• Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?.  106. 2006
• Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells..  106. 2006
• Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma..  106. 2006
• Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma..  106. 2006
• Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma..  106. 2006
• Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee..  106. 2006
• Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study..  104. 2005
• Correlates of breast reconstruction: results from a population-based study..  104. 2005
• Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma..  104. 2005
• Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis..  104. 2005
• Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma..  104. 2005
• Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma..  104. 2005
• Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma..  104. 2005
• Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane..  104. 2005
• Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066..  104. 2005
• Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors..  104. 2005
• The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999..  104. 2005
• Significance of benign endometrial cells in papanicolaou tests from women aged >or=40 years..  105. 2005
• The utility of B72.3, carcinoembryonic antigen, and Leu M-1 in cell blocks: an adjunct to fine-needle aspiration diagnosis of bronchioloalveolar carcinoma of the lung..  105. 2005
• Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy..  104. 2005
• Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence..  104. 2005
• Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy..  104. 2005
• Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up..  104. 2005
• Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters..  103. 2005
• Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study..  103. 2005
• High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib..  103. 2005
• Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy..  103. 2005
• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial..  103. 2005
• Postoperative complications of salvage total laryngectomy..  103. 2005
• Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma..  103. 2005
• Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study..  103. 2005
• A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas..  103. 2005
• Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma..  103. 2005
• Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system..  103. 2005
• Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series..  103. 2005
• Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study..  101. 2004
• A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy..  101. 2004
• Multiple primary soft tissue sarcomas..  101. 2004
• Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis..  101. 2004
• Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480..  101. 2004
• Validation of the postoperative nomogram for 12-year sarcoma-specific mortality..  101. 2004
• Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study..  102. 2004
• Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment..  101. 2004
• Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma..  101. 2004
• Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma..  101. 2004
• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy..  101. 2004
• The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer..  101. 2004
• Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma..  101. 2004
• An academic health center cost analysis of screening mammography: creating a financially viable service..  101. 2004
• Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy..  101. 2004
• Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma..  101. 2004
• The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma..  101. 2004
• The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material..  102. 2004
• Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma..  100. 2004
• The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy..  100. 2004
• Pathologic evaluation of radical cystectomy specimens: a cooperative group report..  100. 2004
• High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma..  100. 2004
• Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma..  100. 2004
• Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial..  100. 2004
• Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors..  100. 2004
• Survivin expression is associated with features of biologically aggressive prostate carcinoma..  100. 2004
• Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial..  98. 2003
• Is endometrial carcinoma intrinsically more aggressive in elderly patients?.  98. 2003
• Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study..  98. 2003
• Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma..  98. 2003
• Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies..  98. 2003
• Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials..  98. 2003
• Craniofacial surgery for malignant skull base tumors: report of an international collaborative study..  98. 2003
• Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma..  98. 2003
• A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma..  98. 2003
• Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy..  98. 2003
• Comparison of ThinPrep and conventional smears in detecting carcinoma in bile duct brushings..  99. 2003
• Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy..  98. 2003
• Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma..  98. 2003
• Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women..  98. 2003
• Symptoms and signs of primary melanoma: important indicators of Breslow depth..  98. 2003
• Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer..  98. 2003
• Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma..  98. 2003
• The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer..  97. 2003
• Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence..  97. 2003
• Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results..  97. 2003
• Sentinel lymph node analysis in patients with sweat gland carcinoma..  97. 2003
• Nipple aspirate fluid cytology in breast carcinoma..  99. 2003
• Can patient selection for bladder preservation be based on response to chemotherapy?.  97. 2003
• Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations..  97. 2003
• Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs..  97. 2003
• Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias..  97. 2003
• Overdiagnosis in chest radiographic screening for lung carcinoma: frequency..  97. 2003
• The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions..  99. 2003
• Compliance with breast-conservation standards for patients with early-stage breast carcinoma..  97. 2003
• Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin..  97. 2003
• Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study..  97. 2003
• Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor..  97. 2003
• Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma..  97. 2003
• Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma..  95. 2002
• Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?.  95. 2002
• Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study..  95. 2002
• An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up..  95. 2002
• Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma..  95. 2002
• Hepatic intraductal oncocytic papillary carcinoma..  95. 2002
• Conventional hemangiopericytoma: modern analysis of outcome..  95. 2002
• Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience..  95. 2002
• Improved outcomes in patients with osteogenic sarcoma of the head and neck..  95. 2002
• Strategies for improving melanoma education and screening for men age >or= 50 years: findings from the American Academy of Dermatological National Skin Cancer Sreening Program..  95. 2002
• Chronic neuroblastoma..  95. 2002
• Factors that influence surgical choices in women with breast carcinoma..  95. 2002
• Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma..  95. 2002
• Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy..  95. 2002
• A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia..  95. 2002
• Carcinoma detection at the breast examination center of Harlem..  95. 2002
• Ethnicity related differences in the survival of young breast carcinoma patients..  95. 2002
• The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease..  95. 2002
• High-grade gliomas in patients with prior systemic malignancies..  94. 2002
• Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8..  94. 2002
• Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma..  94. 2002
• Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients..  94. 2002
• Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma..  94. 2002
• Classification of benign endometrial glandular cells in cervical smears from postmenopausal women..  96. 2002
• Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors..  94. 2002
• Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma..  94. 2002
• Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples..  96. 2002
• Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia..  94. 2002
• Clinicopathologic correlates of solitary fibrous tumors..  94. 2002
• Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma..  94. 2002
• HER-2 profiling and targeting in prostate carcinoma..  94. 2002
• Results of the Lynn Sage Second-Opinion Program for local therapy in patients with breast carcinoma. Changes in management and determinants of where care is delivered..  94. 2002
• Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients..  94. 2002
• Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma..  94. 2002
• Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy..  92. 2001
• Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma..  92. 2001
• Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity..  92. 2001
• Paclitaxel in the multimodality treatment for inflammatory breast carcinoma..  92. 2001
• Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma..  92. 2001
• Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder..  92. 2001
• Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy..  92. 2001
• GD2 synthase: a new molecular marker for detecting neuroblastoma..  92. 2001
• High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas..  92. 2001
• Early lung cancer action project: initial findings on repeat screenings..  92. 2001
• Diagnosis, pathology, staging, treatment, and outcome of epithelial ovarian neoplasia in patients age < 21 years..  91. 2001
• A case-control study of unilateral and bilateral breast carcinoma patients..  91. 2001
• Impact of breast carcinoma on African-American women: the Detroit experience..  91. 2001
• Should the cytologic diagnosis of "atypical squamous cells of undetermined significance" be qualified? An assessment including comparison between conventional and liquid-based technologies..  93. 2001
• Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma..  91. 2001
• Alternative medicine use worldwide: the International Union Against Cancer survey..  91. 2001
• Peritoneovenous shunting for nongynecologic malignant ascites..  91. 2001
• A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases..  91. 2001
• Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast..  91. 2001
• G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting..  91. 2001
• Clinicopathologic analysis of patients with adult rhabdomyosarcoma..  91. 2001
• Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma..  91. 2001
• Localized non-Hodgkin lymphoma involving the thyroid gland..  91. 2001
• The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma..  91. 2001
• Reducing the cost of diagnosis of breast carcinoma: impact of ultrasound and imaging-guided biopsies on a clinical breast practice..  91. 2001
• Social support as a buffer to the psychological impact of stressful life events in women with breast cancer..  91. 2001
• Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease..  91. 2001
• A phase II study of irinotecan in patients with advanced hepatocellular carcinoma..  91. 2001
• Imaging-histologic discordance at percutaneous breast biopsy..  89. 2000
• Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma..  89. 2000
• In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology..  89. 2000
• Is gastric carcinoma different between Japan and the United States?.  89. 2000
• Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma..  89. 2000
• Successful treatment of metastatic retinoblastoma..  89. 2000
• Outcome of cancer pain consultations..  89. 2000
• Prognostic impact of INK4A deletion in Ewing sarcoma..  89. 2000
• Prognostic impact of P53 status in Ewing sarcoma..  89. 2000
• Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes..  89. 2000
• Patterns of detection in patients with cutaneous melanoma..  89. 2000
• Telomerase activity in B-cell non-Hodgkin lymphoma..  89. 2000
• Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study..  89. 2000
• A comparison of staging systems for localized extremity soft tissue sarcoma..  88. 2000
• Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution..  88. 2000
• Identification and characterization of circulating prostate carcinoma cells..  88. 2000
• The schedule of attitudes toward hastened death: Measuring desire for death in terminally ill cancer patients..  88. 2000
• Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group..  88. 2000
• Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules..  88. 2000
• A new American Joint Committee on Cancer staging system for cutaneous melanoma..  88. 2000
• Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma..  88. 2000
• A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181..  88. 2000
• National Cancer Data Base survey of breast cancer management for patients from low income zip codes..  88. 2000
• Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues..  88. 2000
• Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection..  88. 2000
• Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder..  86. 1999
• Extremity and trunk desmoid tumors: a multifactorial analysis of outcome..  86. 1999
• Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face..  86. 1999
• Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age..  86. 1999
• The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia..  86. 1999
• Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma..  86. 1999
• Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma..  86. 1999
• Localized male breast carcinoma and family history. An analysis of 142 patients..  86. 1999
• Cytopathology of insular carcinoma of the thyroid..  87. 1999
• The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9..  86. 1999
• Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma..  86. 1999
• The cytology of extraskeletal Ewing sarcoma..  87. 1999
• A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group..  85. 1999
• B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology..  85. 1999
• Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma..  85. 1999
• Malignant fibrous histiocytoma of the extremity..  85. 1999
• Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma..  85. 1999
• Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy..  85. 1999
• Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma..  85. 1999
• Childhood melanoma survival..  85. 1999
• Genetic changes in the spectrum of neuroendocrine lung tumors..  85. 1999
• Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma..  85. 1999
• Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck..  85. 1999
• Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial..  85. 1999
• Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas..  83. 1998
• Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group..  83. 1998
• Malignant vascular tumors in young patients..  83. 1998
• Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study..  83. 1998
• Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin..  83. 1998
• The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States..  83. 1998
• A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain..  83. 1998
• Gallbladder carcinoma discovered during laparoscopic cholecystectomy: aggressive reresection is beneficial..  83. 1998
• Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma..  83. 1998
• Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery..  83. 1998
• Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma..  82. 1998
• Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors..  82. 1998
• The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma..  82. 1998
• Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge..  82. 1998
• Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study..  82. 1998
• The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant..  82. 1998
• A comparison of screening mammography results from programs for women of different socioeconomic status..  82. 1998
• Prognostic factors for patients with sarcomas of the pelvic bones..  82. 1998
• Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity..  82. 1998
• Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group..  82. 1998
• The role of surgery in the treatment of clinically isolated adrenal metastasis..  82. 1998
• Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery..  82. 1998
• 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma..  80. 1997
• Surgical treatment of 70 patients with brain metastases from breast carcinoma..  80. 1997
• Chest wall rhabdomyosarcoma..  80. 1997
• Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors..  80. 1997
• Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells..  80. 1997
• Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma..  80. 1997
• The conservative management of Paget's disease of the breast with radiotherapy..  80. 1997
• The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S..  80. 1997
• Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors..  80. 1997
• Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus..  80. 1997
• Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy..  80. 1997
• Influence of nativity on cancer mortality among black New Yorkers..  80. 1997
• Fine-needle aspiration biopsy in the diagnosis and management of bone lesions: a study of 450 cases..  81. 1997
• Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group..  79. 1997
• Solitary fibrous tumor. A cytologic-histologic study with clinical, radiologic, and immunohistochemical correlations..  81. 1997
• All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group..  79. 1997
• Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis..  79. 1997
• p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate..  79. 1997
• Patterns of mammographically detected calcifications after breast-conserving therapy associated with tumor recurrence..  79. 1997
• Cutaneous melanoma in patients with sarcoma..  79. 1997
• Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome..  79. 1997
• Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma..  79. 1997
• Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features..  79. 1997
• A national survey of attitudes regarding participation in prostate carcinoma testing..  78. 1996
• A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue..  78. 1996
• Acute complications of central line placement in profoundly thrombocytopenic cancer patients..  78. 1996
• Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds..  78. 1996
• Graft-versus-host disease. Possible higher risk for African American patients..  78. 1996
• The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society..  78. 1996
• Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index..  78. 1996
• Transitions in the care of adolescent and young adult survivors of childhood cancer..  78. 1996
• Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response..  78. 1996
• Treatment of femoral Ewing's sarcoma..  78. 1996
• United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females..  77. 1996
• Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma..  77. 1996
• Post-irradiation malignant mesothelioma..  77. 1996
• The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis..  77. 1996
• Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome..  77. 1996
• Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma..  76. 1995
• Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate..  76. 1995
• The National Cancer Data Base report on pancreatic cancer..  76. 1995
• High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis..  76. 1995
• p53 protein accumulation in tumors of the ampulla of Vater..  76. 1995
• Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster..  76. 1995
• Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin..  76. 1995
• Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma..  76. 1995
• all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial..  76. 1995
• Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel..  76. 1995
• A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma..  75. 1995
• A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma..  75. 1995
• A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer..  75. 1995
• Assessment of response to therapy of primary breast cancer by mammography and physical examination..  75. 1995
• Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis..  75. 1995
• Inadequate adherence to radiotherapy in Latina immigrants with carcinoma of the cervix. Potential impact on disease free survival..  75. 1995
• Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer..  75. 1995
• A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer..  75. 1995
• Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer..  75. 1995
• Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer..  75. 1995
• The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate..  75. 1995
• Lung cancer..  75. 1995
• Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer..  75. 1995
• Dysplastic nevi as a melanoma risk factor in patients with familial melanoma..  74. 1994
• Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse..  74. 1994
• A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance..  74. 1994
• A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer..  74. 1994
• In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer..  74. 1994
• Conservative surgery for giant cell tumors of the sacrum. The role of cryosurgery as a supplement to curettage and partial excision..  74. 1994
• Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors..  74. 1994
• The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem..  74. 1994
• A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors..  74. 1994
• Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas..  74. 1994
• Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas..  74. 1994
• The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations..  74. 1994
• Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas..  73. 1994
• Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases..  73. 1994
• The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience..  73. 1994
• Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay..  73. 1994
• Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care..  73. 1994
• Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy..  73. 1994
• Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale..  73. 1994
• Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma..  73. 1994
• Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update..  73. 1994
• Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia..  73. 1994
• Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy..  73. 1994
• The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin..  73. 1994
• Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer..  73. 1994
• Therapy of venous thromboembolism in patients with brain metastases..  73. 1994
• Defining the invasive phenotype of proximal gastric cancer cells..  73. 1994
• Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody..  73. 1994
• Partial nephrectomy for renal cell carcinoma with a normal opposite kidney..  73. 1994
• Phase II trial of gemcitabine in patients with advanced gastric cancer..  73. 1994
• The effect of age at diagnosis on outcome in rhabdomyosarcoma..  73. 1994
• Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial..  72. 1993
• CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus..  72. 1993
• Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol..  72. 1993
• Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft tissue sarcomas..  72. 1993
• Liposarcoma in patients younger than or equal to 22 years of age..  72. 1993
• Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis..  72. 1993
• Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy..  72. 1993
• Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder..  72. 1993
• Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential..  72. 1993
• Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma..  72. 1993
• The clinical spectrum of ocular lymphoma..  72. 1993
• A phase II trial of carboplatin in patients with advanced APUD tumors..  72. 1993
• Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors..  72. 1993
• Prognosis of operable squamous cell carcinoma of the esophagus. Relationship with clinicopathologic features and DNA ploidy..  72. 1993
• Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma..  71. 1993
• The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer..  71. 1993
• Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment..  71. 1993
• Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial..  71. 1993
• Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment..  71. 1993
• Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study..  71. 1993
• A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases..  71. 1993
• Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma..  71. 1993
• Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin..  71. 1993
• Phase II trial of carboplatin and etoposide in metastatic breast cancer..  71. 1993
• A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy..  71. 1993
• The role of neoadjuvant hormonal manipulation in localized prostatic cancer..  71. 1993
• Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience..  71. 1993
• Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy..  71. 1993
• Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy..  70. 1992
• Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy..  70. 1992
• Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers..  70. 1992
• Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B..  70. 1992
• A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site..  70. 1992
• Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma..  70. 1992
• Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect..  70. 1992
• Prognostic significance of DNA quantitation in stage D1 prostate carcinoma with the use of image analysis..  70. 1992
• The National Polyp Study. Design, methods, and characteristics of patients with newly diagnosed polyps. The National Polyp Study Workgroup..  70. 1992
• Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas..  70. 1992
• Detection of local recurrence after conservative therapy for breast carcinoma..  70. 1992
• Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience..  70. 1992
• Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis..  70. 1992
• Surgical treatment for benign prostatic hyperplasia..  70. 1992
• Is screening for breast cancer cost-effective?.  69. 1992
• Legal aspects, legislative effect, cost effectiveness, and barriers to breast cancer screening..  69. 1992
• Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease..  69. 1992
• Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump..  69. 1992
• Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer..  69. 1992
• Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience..  69. 1992
• The indications for elective treatment of the neck in cancer of the major salivary glands..  69. 1992
• A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer..  69. 1992
• High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated..  69. 1992
• A flow cytometric study of non-small cell lung cancer classified as T1N0..  69. 1992
• Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors..  68. 1991
• Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast..  68. 1991
• An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2..  68. 1991
• Transurethral resection of the prostate and metastatic prostate cancer..  68. 1991
• Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B..  68. 1991
• Localization of endocrine tumors of the pancreas with endoscopic ultrasonography..  68. 1991
• A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma..  68. 1991
• A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors..  68. 1991
• Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia..  68. 1991
• A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma..  68. 1991
• Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure..  68. 1991
• High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma..  68. 1991
• Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer..  67. 1991
• Retinoblastoma. The long-term appearance of radiated intraocular tumors..  67. 1991
• Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma..  67. 1991
• Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features..  67. 1991
• Extracranial primitive neuroectodermal tumors. The Memorial Sloan-Kettering Cancer Center experience..  67. 1991
• Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy..  67. 1991
• Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989)..  67. 1991
• Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors..  67. 1991
• A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus..  67. 1991
• Combined surgical resection and iridium 192 implantation for locally advanced and recurrent desmoid tumors..  67. 1991
• Insulin secretion and action in patients with pancreatic cancer..  67. 1991
• Two-drug therapy in patients with metastatic germ cell tumors..  67. 1991
• Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity..  66. 1990
• The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro..  66. 1990
• The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors..  66. 1990
• A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851..  66. 1990
• A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies..  66. 1990
• Comparison of the conventional method of lymph node staging with a comprehensive fat-clearing method for gastric adenocarcinoma..  66. 1990
• Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer..  66. 1990
• Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors..  66. 1990
• Dose-intensive use of cyclophosphamide in ablation of neuroblastoma..  66. 1990
• Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer..  66. 1990
• The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients..  66. 1990
• A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma..  66. 1990
• Delayed central nervous system (CNS) radiation in childhood CNS acute lymphoblastic leukemia. Results of a pilot trial..  66. 1990
• Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome-specific DNA probes..  66. 1990
• The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity..  66. 1990
• Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors..  65. 1990
• Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma..  65. 1990
• DNA content of rectal scrapings from individuals at low and high risk for the development of colorectal cancer. A feasibility study..  64. 1989
• Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia..  64. 1989
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse..  64. 1989
• Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma..  64. 1989
• Small cell carcinoma of the esophagus. The Memorial Hospital experience 1970 to 1987..  64. 1989
• The prognostic value of histologic subtypes in primary extremity liposarcoma..  64. 1989
• Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients..  63. 1989
• Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood..  63. 1989
• Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates..  63. 1989
• Primary central nervous system lymphoma in AIDS. Results of radiation therapy..  63. 1989
• Interstitial brachytherapy for metastatic brain tumors..  63. 1989
• Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement..  63. 1989
• Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors..  63. 1989
• The problem of neck relapse in early stage supraglottic larynx cancer..  63. 1989
• Alveolar soft-part sarcoma. A clinico-pathologic study of half a century..  63. 1989
• Peripheral T-cell lymphoma..  63. 1989
• Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behavior..  62. 1988
• Significance of systemic mast cell disease with associated hematologic disorders..  62. 1988
• Low-grade soft tissue sarcomas of the extremities. Analysis of risk factors for metastasis..  62. 1988
• AIDS-related lymphoid neoplasia. The Memorial Hospital experience..  61. 1988
• Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness..  61. 1988
• Patient compliance with aggressive multimodal therapy in locally advanced breast cancer..  61. 1988
• Cholecystectomy and adenomatous polyps of the colon in women..  61. 1988
• Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial..  60. 1987
• A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B..  60. 1987
• Distinguishing features of primary hyperparathyroidism in patients with breast cancer..  60. 1987
• The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma..  60. 1987
• Quality of life measurement in testicular cancer patients..  60. 1987
• The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain..  60. 1987
• The practical use of tumor marker determination in bladder washing specimens. Assessing the urothelium of patients with superficial bladder cancer..  60. 1987
• Malignant lymphomas in a population at risk for acquired immune deficiency syndrome..  60. 1987
• Abnormal colony formation and prostaglandin E responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy..  60. 1987
• Monoclonal antibodies in urologic oncology..  60. 1987
• Strategies for the management of recurrent and advanced urologic cancers. Quality of life..  60. 1987
• Toxicity of intravesical BCG and its management in patients with superficial bladder tumors..  60. 1987
• Urologic cancer. Methods of early detection and future developments..  60. 1987
• Testicular failure in patients with extragonadal germ cell tumors..  60. 1987
• The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma..  59. 1987
• Acute chest pain syndrome during bleomycin infusions..  59. 1987
• Smoking, body weight, and early-stage endometrial cancer..  59. 1987
• Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma..  59. 1987
• Intermittent endocrine therapy for advanced prostate cancer..  58. 1986
• A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck cancer..  58. 1986
• The treatment of single brain metastasis from non-oat cell lung carcinoma. Surgery and radiation versus radiation therapy alone..  58. 1986
• Thymomas. A review of 169 cases, with particular reference to results of surgical treatment..  58. 1986
• Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer..  57. 1986
• Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors..  57. 1986
• Limb preservation and tumor control in the treatment of popliteal and antecubital soft tissue sarcomas..  57. 1986
• Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors..  57. 1986
• Transrectal ultrasonography for prostatic cancer. II. The response of the prostate to definitive radiotherapy..  57. 1986
• Small cell carcinoma cell lines contain opioid peptides and receptors..  57. 1986
• Intraluminal radiation therapy in the management of malignant biliary obstruction..  57. 1986
• Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung..  56. 1985
• Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients..  56. 1985
• Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy..  56. 1985
• Metastatic neuroblastoma and testicular involvement..  56. 1985
• Fasting plasma amino acid levels in cancer patients..  56. 1985
• Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx..  56. 1985
• Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases..  56. 1985
• HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification..  55. 1985
• Terminal deoxynucleotidyl transferase activity in childhood leukemia..  55. 1985
• A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk..  55. 1985
• Correlation of erythrocyte and plasma levels of zinc, copper, and iron with evidence of metastatic spread in cancer patients..  55. 1985
• Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients..  55. 1985
• Glucose intolerance in sarcoma patients..  54. 1984
• Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report..  54. 1984
• Metabolic consequences of nutritional support of the cancer patient..  54. 1984
• Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer..  54. 1984
• New therapeutic approaches for brain tumors..  54. 1984
• Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy..  54. 1984
• T-lymphocyte subpopulations in B-cell-derived non-Hodgkin's lymphomas and Hodgkin's disease..  54. 1984
• Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide..  54. 1984
• Intracranial metastases in prostate cancer..  53. 1984
• NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma..  53. 1984
• Treatment of diffuse poorly differentiated lymphocytic lymphoma. An analysis of prognostic variables..  53. 1984
• Testicular function following bone marrow transplantation performed during or after puberty..  53. 1984
• Comparison of antigen expression of human renal cancers in vivo and in vitro..  53. 1984
• Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma?.  53. 1984
• Intraarterial versus intravenous adriamycin in the rabbit Vx-2 tumor system..  53. 1984
• Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer..  53. 1984
• Vertebral body resection in the treatment of cancer involving the spine..  53. 1984
• Whole-body protein metabolism in cancer-bearing patients. Effect of total parenteral nutrition and associated serum insulin response..  53. 1984
• Adult non-Hodgkin's lymphoma. Correlation of cell surface marker phenotype with prognosis, the new working formulation, and the Rappaport and Lukes-Collins histomorphologic schemes..  52. 1983
• Planned preoperative cisplatin and radiation therapy for locally advanced bladder cancer..  52. 1983
• Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group..  52. 1983
• Cooperative groups and community hospitals. Measurement of impact in the community hospitals..  52. 1983
• Reactivity of monoclonal antibodies Leu 1 and OKT1 with malignant human lymphoid cells. Correlation with conventional cell markers..  52. 1983
• Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities..  52. 1983
• Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis..  51. 1983
• Severe pneumococcal infection in patients with neoplastic disease..  51. 1983
• Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder..  51. 1983
• Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma..  51. 1983
• Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone..  51. 1983
• Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer..  51. 1983
• Association of depressed mixed lymphocyte reactivity with the development of bladder carcinoma in patients with papillomas..  51. 1983
• Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep)..  51. 1983
• The non-Hodgkin's lymphomas. I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969..  51. 1983
• VAB-6 combination chemotherapy in resected stage II-B testis cancer..  51. 1983
• Treatment of advanced esophageal cancer..  50. 1982
• Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience..  50. 1982
• Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma..  50. 1982
• Intravenous cisplatin for superficial bladder tumors..  50. 1982
• Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up..  50. 1982
• Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma..  50. 1982
• Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases..  50. 1982
• Role of chemotherapy and surgery in the treatment of thoracic metastases from nonseminomatous germ cell testis tumor..  50. 1982
• Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone..  50. 1982
• An evaluation of automated flow cytometry (FCM) in detection of carcinoma in situ of the urinary bladder..  50. 1982
• Intravesical cisplatin for superficial bladder tumors..  50. 1982
• Detection and follow-up of carcinoma of the urinary bladder by flow cytometry..  50. 1982
• Cell kinetics in acute leukemia: a critical reevaluation based on new data..  50. 1982
• The immunologic characterization of 40 extranodal lymphoid infiltrates: usefulness in distinguishing between benign pseudolymphoma and malignant lymphoma..  49. 1982
• Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables..  49. 1982
• A controlled, prospective, randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patient..  49. 1982
• Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin..  49. 1982
• Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy..  49. 1982
• Resting and activity energy expenditure during total parenteral nutrition in rats with methylcholanthrene-induced sarcoma..  49. 1982
• The impact of total parenteral nutrition on liver function tests in patients with cancer..  49. 1982
• Correlation of histochemical and biochemical analyses of androgen binding in prostatic cancer: relation to therapeutic response..  49. 1982
• Preoperative irradiation and cystectomy for bladder cancer..  49. 1982
• Immunoregulation by blasts from null cell and T-cell leukemias: help and suppression of T-cell proliferative responses to mitogens..  49. 1982
• Comparison of the response to PHA and suppressor macrophage function in different age groups of cancer patients and healthy controls..  48. 1981
• Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer..  48. 1981
• Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol..  48. 1981
• Small cell lung cancer: analysis of treatment factors contributing to prolonged survival..  48. 1981
• Osteonecrosis in patients with malignant lymphoma: a review of twenty-five cases..  48. 1981
• Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease..  48. 1981
• Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer..  48. 1981
• Combined modality therapy of esophageal carcinoma..  48. 1981
• Combined chemotherapy and surgery in treatment of advanced germ-cell tumors..  47. 1981
• Ewing's sarcoma: ten-year experience with adjuvant chemotherapy..  47. 1981
• Metabolic alterations in a noncachectic animal tumor system..  47. 1981
• Adjuvant chemotherapy combination of vinblastine, actinomycin D, Bleomycin, and Chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor..  47. 1981
• Tumor markers in advanced nonseminomatous testicular cancer..  47. 1981
• Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer..  47. 1981
• Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor..  46. 1980
• Immunotherapy with oral BCG and serial immune evaluation in childhood lymphoblastic leukemia following three years of chemotherapy..  46. 1980
• Serum zinc, copper, and the Cu/Zn ratio in patients with benign and malignant breast lesions..  46. 1980
• Pharmacokinetics of gallium nitrate in man..  46. 1980
• A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease..  46. 1980
• Analysis of multiple cell markers in acute leukemia complicating Hodgkin's disease..  46. 1980
• Extracardiac rhabdomyoma: a clinicopathologic study and review of the literature..  46. 1980
• Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia..  46. 1980
• Orbital lymphoid neoplasms: a clinicopathologic study of 60 patients..  46. 1980
• A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens..  46. 1980
• The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up report..  46. 1980
• Prognostic significance of serum lactate dehydrogenase in malignant lymphoma..  46. 1980
• Subpopulations of human T lymphocytes. VI. Analysis of cell markers in acute lymphoblastic leukemia with special reference to Fc receptor expression on E-rosette-forming blasts..  46. 1980
• In vivo utilization of substrate by human sarcoma-bearing limbs..  45. 1980
• A study of adriamycin-reduced wound breaking strenght in rats. An evaluation by light and electron microscopy, induction of collagen maturation, and hydroxyproline content..  45. 1980
• Time dependent effects of adriamycin and x-ray therapy on wound healing in the rat..  45. 1980
• Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications..  45. 1980
• Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation..  45. 1980
• Influenza immunization of children with neoplastic diseases..  45. 1980
• Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection..  45. 1980
• Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B..  45. 1980
• Effect of short-term levamisole therapy on delayed hypersensitivity..  45. 1980
• Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment..  44. 1979
• A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II..  44. 1979
• Acute non-lymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: cytogenetic studies..  44. 1979
• Acute nonlymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: clinical studies..  44. 1979
• A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non-Hodgkin's lymphoma..  43. 1979
• The quantitative and qualitative impairment of wound healing by adriamycin..  43. 1979
• A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma..  43. 1979
• Anticoagulation and high dose liver radiation: a preliminary report..  43. 1979
• The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine..  43. 1979
• Cardiac candidiasis in cancer patients..  41. 1978
• Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer..  41. 1978
• Prophylactic heparin therapy in acute promyelocytic leukemia..  41. 1978
• Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma..  41. 1978
• Results of combined chemo-surgical therapy for pulmonary metastases from testicular carcinoma..  41. 1978
• Immunologic reactivity in patients with primary operable breast cancer..  41. 1978
• NMR in cancer. X. A malignancy index to discriminate normal and cancerous tissue..  41. 1978
• NMR in cancer. XI. Application of the NMR malignancy index to human gastro-intestinal tumors..  41. 1978
• High dose methotrexate with citrovorum factor in adult resistant lymphoma..  40. 1977
• The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy..  40. 1977
• Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique..  40. 1977
• The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation..  40. 1977
• Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up..  40. 1977
• Patterns of second malignant neoplasms in children..  40. 1977
• The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: significance and clinicopathologic correlation..  40. 1977
• Radiotherapy results for nodular sclerosing Hodgkin's disease after clinical staging..  39. 1977
• A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA..  39. 1977
• The role of bone marrow aspiration and biopsy in detecting marrow involvement by nonhematologic malignancies..  38. 1976
• Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study..  38. 1976
• Proximal tubular adenomas of kidney with so-called oncocytic features. A clinicopathologic study of 13 cases of a rarely reported neoplasm..  38. 1976
• Abdominal irradiation in non-Hodgkin's lymphomas..  37. 1976
• Non-Hodgkin's lymphomas of stage III extent. Is total lymphoid irradiation appropriate treatment?.  37. 1976
• Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens..  37. 1976
• Decreased risk of radiation-associated second malignant neoplasms in actinomycin-D-treated patients..  37. 1976
• Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia..  36. 1975
• Treatment of acute leukemia in adults..  36. 1975
• Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease..  36. 1975
• Studies of cellular proliferation in human leukemia. VIII. The generation time and growth fraction in lymphosarcoma in a leukemic phase during advanced and early relapsing disease..  36. 1975
• Explorotory study of proton radiation therapy using large field techniques and fractionated dose schedules..  35. 1975
• Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors..  35. 1975
• Full thickness chest wall resection for recurrent breast carcinoma involving the bony chest wall..  35. 1975
• Indications for pleurectomy in malignant effusion..  35. 1975
• Multidisciplinary treatment of embryonal rhabdomyosarcoma in children..  35. 1975
• Of birds and mice and men: comments on the use of animal models and molecular hybridization in the search for human tumor viruses..  34. 1974
• Lymphography in mycosis fungoides..  34. 1974
• The role of lymphography in patients with ovarian cancer..  34. 1974
• Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol)..  33. 1974
• Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU..  33. 1974
• Prognostic signs and the management of the mycosis fungoides..  32. 1973
• Proceedings: Combination therapy of urogenital embryonal rhabdomyosarcoma in children..  32. 1973
• Non-Hodgkin's lymphomas. V. Results of radiotherapy..  32. 1973
• Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas..  32. 1973
• Liver-spleen scan in Hodgkin's disease..  31. 1973
• Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases..  31. 1973
• Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis..  31. 1973
• Reappraisal of surgical management of sarcoma of the buttock..  31. 1973
• Acute myelocytic leukemia in adults..  30. 1972
• Chondroblastoma of bone. A clinicopathologic and electron microscopic study..  29. 1972
• Studies on cellular proliferation in human leukemia. VII. Cytokinetic behavior of neoplastic cells in a patient with reticulum cell sarcoma in a leukemic phase..  28. 1971
• Aneurysmal bone cysts. A clinicopathologic study of 66 cases..  26. 1970
• Incontinuity versus discontinuous lymph node dissection for malignant melanoma..  26. 1970
• Prognostic significance of lymph node dissection in the treatment of malignant melanoma..  26. 1970
• Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease..  26. 1970
• Studies of cellular proliferation in human leukemia. IV. Behavior of normal hemotopoietic cells in 3 adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days..  26. 1970
• Studies of cellular proliferation in human leukemia. 3. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days..  25. 1970
• Studies of cellular proliferation in human leukemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukemia..  25. 1970
• Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors..  25. 1970
• Toxicity of E. coli L-asparaginase in man..  25. 1970
• Heterotransplantability of human cell lines derived from leukemia and lymphomas into immunologically tolerant rats..  24. 1969
• Treatment of adult acute leukemia with arabinosylcytosine and thioguanine..  23. 1969
• Hetero- transplantation of human cell lines from Burkitt's tumors and acute leukemia into newborn rats..  23. 1969
• Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases..  23. 1969
• Two histologically different primary carcinomas of the lung. A review of the literature and presentation of a case..  22. 1968
• Continuous culture of seven new cell lines (SK-L1 to 7) from patients with acute leukemia..  20. 1967
• Electron microscopic study of human leukemic cells in tissue culture..  20. 1967
• Kinetics of proliferation of cancer cells in neoplastic effusions in man..  18. 1965
• RELATIONSHIP BETWEEN CELL TYPE, GLUCOSE CONCENTRATION, AND RESPONSE TO TREATMENT IN NEOPLASTIC EFFUSIONS..  17. 1964
• Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver..  15. 1962
• Antimetabolite-metabolite cancer chemotherapy using continuous intra-arterial methotrexate with intermittent intramuscular citrovorum factor. Method of therapy..  14. 1961
• Reply to The risk factors of upgrading in prostate cancer..  126. 2020
• Reply to Hope, optimism, and the importance of caregivers in end-of-life care..  125. 2019
• Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?.  125. 2019
• Reply to Distinguishing between CISNET model results versus CISNET models..  124. 2017
• Reply to Opportunity cost of annual screening mammography..  124. 2017
• Reply to "Twistin' the night away": Fertility preservation in young adult female cancer survivors..  123. 2016
• Reply to discrepant results for smoking and cessation among electronic cigarette users..  121. 2015
• Reply to US lung cancer trends by histologic type..  121. 2014
• Reply to Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients..  120. 2013
• Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer..  117. 2011
• Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer..  117. 2010
• Increasing the pool of academically oriented African-American medical and surgical oncologists..  98. 2003
• Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma..  98. 2003
• Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma..  97. 2003
• Pathologic evaluation of radical cystectomy specimens..  95. 2002
• Progression of T1 bladder tumors: better staging or better biology?.  86. 1999
• Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease..  82. 1998
• Autologous bone marrow transplantation in children with advanced neuroblastoma..  76. 1995
• Reply to "Switching the scope from 'how to identify cancer survivors' to 'who is participating in cancer survivorship research': A proposal for a new focus". 2022
• Comparative study of infectious complications of different types of chronic central venous access devices. 1995
• Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. 2008
• Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy. 2006
• Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. 2004
• Overview of the summit meeting evaluating research in African-American women. 2003
• Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. 2000
• The need for multilevel supportive care infrastructure for cancer caregivers..  130. 2024
• Let's ask the patient: Self-reported quality-of-life measures help to predict kidney cancer mortality..  128. 2021
• Young adult caregivers' perceptions of cancer misinformation on social media: Response to Warner et al..  127. 2020
• Nasopharynx cancer: Induction or adjuvant? That is the question..  126. 2020
• Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer..  124. 2018
• Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!.  123. 2017
• Missing the mark in FGFR1-amplified squamous cell cancer of the lung..  122. 2016
• Specialty care for adult survivors of childhood cancer..  121. 2015
• Quality lung cancer screening protects quality of life: no harm, no foul..  120. 2014
• Proceedings of the First International Inflammatory Breast Cancer Conference..  116. 2010
• Radiation versus resection for Merkel cell carcinoma..  116. 2010
• High-risk, high-grade (T1G3) bladder cancer: models versus reality..  115. 2009
• "Limited" prostate cancer on biopsy: a note of caution..  112. 2008
• Agonizing over AGUS..  87. 1999
• Detectable tumor cells in the blood and bone marrow: smoke or fire?.  83. 1998
• Thyroid carcinoma: implications of prognostic factors..  83. 1998
• The natural history of clinical prostate carcinoma..  80. 1997
• BRCA1. A new marker in the management of patients with breast cancer?.  77. 1996
• The natural history of ductal carcinoma in situ. Implications for clinical decision making..  76. 1995
• Optimal treatment for advanced seminoma?.  72. 1993
• Radical surgery for gastric cancer. A review of the Japanese experience..  64. 1989
• The METeoric rise of MET in lung cancer. 2020
• The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. 2020
• Effects of psychosocial interventions on meaning and purpose in adults with cancer: A systematic review and meta-analysis. 2019
• Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? 2018
• Irradiation and immunotherapy: From concept to the clinic. 2016
• Social well-being among adolescents and young adults with cancer: A systematic review. 2016
• Immunotherapy in hepatocellular carcinoma: Primed to make a difference? 2015
• Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. 2015
• Therapeutic targeting of tumor suppressor genes. 2014
• Small cell lung cancer: where do we go from here? 2014
• Treating advanced hepatocellular carcinoma: How to get out of first gear. 2014
• Practical management of patients with chronic myeloid leukemia. 2011
• Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. 2010
• An updated catalog of prostate cancer predictive tools. 2008
• Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. 2008
• Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. 2005
• Gemcitabine-related radiation recall preferentially involves internal tissue and organs. 2004
• Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. 2002
• Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. 1997
• Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. 1993
• Defining disease modification in myelofibrosis in the era of targeted therapy. 2022
• Cancer-related inflammation and depressive symptoms: Systematic review and meta-analysis. 2022
• Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. 2021
• Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. 2020
• Risk-reducing salpingectomy: Let us be opportunistic. 2017
• Current management and future directions in metastatic pancreatic adenocarcinoma. 2016
• Novel endoscopic diagnosis for bladder cancer. 2014
• Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. 2010
• Manipulating the chemokine-chemokine receptor network to treat cancer. 2007
• Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. 1988
• Proliferative myositis of the masseter muscle. A case report and a review of the literature. 1983

Identity

ISO Abbreviation

• Cancer

Linking ISSN

• 0008-543X

International Standard Serial Number (ISSN)

• 0008-543X

Electronic International Standard Serial Number (EISSN)

• 1097-0142